Alkem Laboratories has announced a key senior management change with the resignation of Mr. Vijay Shetty, Senior Vice President-Global Distribution Supply Chain, effective December 12, 2025. The pharmaceutical company made this disclosure under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations.

Resignation Details

The company informed stock exchanges that Mr. Shetty has tendered his resignation to pursue better opportunities outside the organization. His departure represents a significant change in the senior management team responsible for global distribution and supply chain operations.

Timeline and Process

According to internal communications, Mr. Shetty initially submitted his resignation on October 13, 2025. However, after discussions with the company's CEO and management team, his last working day was extended to December 12, 2025. This timeline suggests a structured transition process to ensure continuity in the company's global distribution and supply chain functions.

Regulatory Compliance

Alkem Laboratories has fulfilled its disclosure obligations under SEBI regulations by notifying both the National Stock Exchange of India Limited and BSE Limited about this senior management change. The company provided all required details as per Regulation 30 read with Schedule III, Part A, Para A(7) of the SEBI LODR Regulations and the SEBI Master Circular dated November 11, 2024.

Corporate Communication

The resignation letter reveals Mr. Shetty's appreciation for the support and guidance received during his tenure. He expressed gratitude toward the management, colleagues, and team members for their cooperation throughout his time with the pharmaceutical company. This professional transition reflects the company's commitment to maintaining positive relationships even during leadership changes.

The disclosure has been made available on the company's official website at www.alkemlabs.com , ensuring transparency for all stakeholders. Alkem Laboratories continues to operate its global distribution and supply chain functions while managing this senior management transition.

Alkem Laboratories Limited successfully completed a Good Manufacturing Practice (GMP) inspection at its Daman manufacturing facility, conducted by the Malta Medicines Authority. The inspection, which took place from December 5-9, demonstrated the pharmaceutical company's adherence to international quality standards, with no critical observations recorded.

Inspection Results Overview

The Malta Medicines Authority's comprehensive assessment of Alkem's Daman facility revealed a generally positive compliance status. The inspection results breakdown provides insight into the facility's operational standards:

The absence of critical observations represents a significant achievement for Alkem Laboratories, indicating that the facility's core manufacturing processes and quality control systems meet the stringent requirements set by European regulatory authorities.

Regulatory Compliance and Remediation

Alkem Laboratories has committed to addressing all identified observations within the regulatory timeframe specified by the Malta Medicines Authority. The company's proactive stance on resolving the three major observations and several minor issues demonstrates its dedication to maintaining the highest manufacturing standards.

The pharmaceutical company's swift response to regulatory feedback is crucial for maintaining its operational licenses and market access in European territories. Timely closure of these observations will ensure continued compliance with Good Manufacturing Practice guidelines.

Strategic Implications

The successful GMP inspection outcome strengthens Alkem Laboratories' position in international pharmaceutical markets, particularly within the European Union where Malta serves as a regulatory gateway. The clean inspection record, free from critical observations, enhances the company's credibility with regulatory bodies and potential business partners.

This positive regulatory milestone supports Alkem's ongoing expansion strategy and reinforces investor confidence in the company's operational capabilities. The Daman facility's compliance status positions it favorably for continued pharmaceutical manufacturing and potential capacity expansion.

Industry Impact

The GMP inspection results reflect Alkem Laboratories' commitment to maintaining international quality standards in pharmaceutical manufacturing. As the company works to address the identified observations, the focus remains on continuous improvement and regulatory excellence across all manufacturing operations.